Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase 1/2 2Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Dermatologic 1

Conditions

Multiple Myeloma 41Neoplasms, Plasma Cell 16Lymphoma, Non-Hodgkin 13Lymphoma 13Leukemia, Myeloid, Acute 13Leukemia 13Myelodysplastic Syndromes 11Hodgkin Disease 10Lymphoma, Mantle-Cell 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Congenital Abnormalities 4Neuroblastoma 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Hematologic Neoplasms 3Graft vs Host Disease 3Burkitt Lymphoma 3Smoldering Multiple Myeloma 2Neoplasms 2Myeloproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Juvenile 2

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Melphalan × Clear all
NCT00793650 2012-08-30

Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

Emory University

Phase 1/2 Terminated
39 enrolled 9 charts
Plasma cell

Multiple Myeloma, Neoplasms

NCT00421811 2010-12-28

A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan

Adherex Technologies, Inc.

Phase 1/2 Completed
56 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡